Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
Philippe Moreau(Centre National de la Recherche Scientifique), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Surbhi Sidana(Palo Alto University), Ajay K. Nooka(Emory University), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Lionel Karlin(Hôpital Lyon Sud), María‐Victoria Mateos(Hospital Clínico San Carlos), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Rian Van Rampelbergh(Janssen (Belgium)), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Hareth Nahi(Karolinska University Hospital), Albert Oriol(Institut Català d'Oncologia), Arnob Banerjee(Johnson & Johnson (United States)), Thomas G. Martin(University of California San Francisco Medical Center), Lotfi Benboubker, Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Lixia Pei(Janssen (United States)), Michel Delforge(KU Leuven), Laura Rosiñol(Universitat de Barcelona), Niels WCJ van de Donk(Vrije Universiteit Amsterdam), Yunsi Olyslager(Janssen (Belgium))
Cited by 2
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k